Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Robert James Glynn, Sc.D., Ph.D.

Co-Author

This page shows the publications co-authored by Robert Glynn and Paul Ridker.
Connection Strength

17.200
  1. Inflammation, venous thromboembolism, and what we can do about it. Eur Heart J. 2018 10 14; 39(39):3615-3617.
    View in: PubMed
    Score: 0.831
  2. Modulation of the interleukin-6 signalling pathway and incidence rates of atherosclerotic events and all-cause mortality: analyses from the Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS). Eur Heart J. 2018 10 07; 39(38):3499-3507.
    View in: PubMed
    Score: 0.830
  3. Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial. Lancet. 2012 Aug 11; 380(9841):565-71.
    View in: PubMed
    Score: 0.542
  4. The JUPITER Trial: responding to the critics. Am J Cardiol. 2010 Nov 01; 106(9):1351-6.
    View in: PubMed
    Score: 0.475
  5. Interpretation of Mendelian randomization studies and the search for causal pathways in atherothrombosis: the need for caution. Metab Syndr Relat Disord. 2010 Dec; 8(6):465-9.
    View in: PubMed
    Score: 0.474
  6. Rosuvastatin for primary prevention among individuals with elevated high-sensitivity c-reactive protein and 5% to 10% and 10% to 20% 10-year risk. Implications of the Justification for Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) trial for "intermediate risk". Circ Cardiovasc Qual Outcomes. 2010 Sep; 3(5):447-52.
    View in: PubMed
    Score: 0.473
  7. Relation of baseline high-sensitivity C-reactive protein level to cardiovascular outcomes with rosuvastatin in the Justification for Use of statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER). Am J Cardiol. 2010 Jul 15; 106(2):204-9.
    View in: PubMed
    Score: 0.466
  8. JUPITER, rosuvastatin, and the European Medicines Agency. Lancet. 2010 Jun 12; 375(9731):2071.
    View in: PubMed
    Score: 0.464
  9. Rosuvastatin for primary prevention in older persons with elevated C-reactive protein and low to average low-density lipoprotein cholesterol levels: exploratory analysis of a randomized trial. Ann Intern Med. 2010 Apr 20; 152(8):488-96, W174.
    View in: PubMed
    Score: 0.462
  10. Efficacy of rosuvastatin among men and women with moderate chronic kidney disease and elevated high-sensitivity C-reactive protein: a secondary analysis from the JUPITER (Justification for the Use of Statins in Prevention-an Intervention Trial Evaluating Rosuvastatin) trial. J Am Coll Cardiol. 2010 Mar 23; 55(12):1266-1273.
    View in: PubMed
    Score: 0.458
  11. A randomized trial of rosuvastatin in the prevention of venous thromboembolism. N Engl J Med. 2009 Apr 30; 360(18):1851-61.
    View in: PubMed
    Score: 0.429
  12. Tracking of high-sensitivity C-reactive protein after an initially elevated concentration: the JUPITER Study. Clin Chem. 2009 Feb; 55(2):305-12.
    View in: PubMed
    Score: 0.421
  13. D-dimer and duration of anticoagulation. N Engl J Med. 2007 Jan 25; 356(4):422-3; author reply 423.
    View in: PubMed
    Score: 0.369
  14. Low-intensity versus conventional-intensity warfarin for prevention of recurrent venous thromboembolism. N Engl J Med. 2003 Nov 27; 349(22):2164-7; author reply 2164-7.
    View in: PubMed
    Score: 0.296
  15. The neutrophil-lymphocyte ratio and incident atherosclerotic events: analyses from five contemporary randomized trials. Eur Heart J. 2021 03 01; 42(9):896-903.
    View in: PubMed
    Score: 0.245
  16. Inhibition of Interleukin-1ß and Reduction in Atherothrombotic Cardiovascular Events in the CANTOS Trial. J Am Coll Cardiol. 2020 10 06; 76(14):1660-1670.
    View in: PubMed
    Score: 0.238
  17. Comparison of interleukin-6, C-reactive protein, and low-density lipoprotein cholesterol as biomarkers of residual risk in contemporary practice: secondary analyses from the Cardiovascular Inflammation Reduction Trial. Eur Heart J. 2020 08 14; 41(31):2952-2961.
    View in: PubMed
    Score: 0.236
  18. Effects of Interleukin-1ß Inhibition on Incident Anemia: Exploratory Analyses From a Randomized Trial. Ann Intern Med. 2020 04 21; 172(8):523-532.
    View in: PubMed
    Score: 0.230
  19. Adverse Effects of Low-Dose Methotrexate: A Randomized Trial. Ann Intern Med. 2020 03 17; 172(6):369-380.
    View in: PubMed
    Score: 0.228
  20. Effects of Interleukin-1ß Inhibition on Blood Pressure, Incident Hypertension, and Residual Inflammatory Risk: A Secondary Analysis of CANTOS. Hypertension. 2020 02; 75(2):477-482.
    View in: PubMed
    Score: 0.226
  21. Anti-Inflammatory Therapy With Canakinumab for the Prevention of Hospitalization for Heart Failure. Circulation. 2019 03 05; 139(10):1289-1299.
    View in: PubMed
    Score: 0.213
  22. Low-Dose Methotrexate for the Prevention of Atherosclerotic Events. N Engl J Med. 2019 02 21; 380(8):752-762.
    View in: PubMed
    Score: 0.209
  23. Rationale and design of the Pemafibrate to Reduce Cardiovascular Outcomes by Reducing Triglycerides in Patients with Diabetes (PROMINENT) study. Am Heart J. 2018 12; 206:80-93.
    View in: PubMed
    Score: 0.207
  24. Relationship of Interleukin-1ß Blockade With Incident Gout and Serum Uric Acid Levels: Exploratory Analysis of a Randomized Controlled Trial. Ann Intern Med. 2018 10 16; 169(8):535-542.
    View in: PubMed
    Score: 0.207
  25. Inhibition of Interleukin-1ß by Canakinumab and Cardiovascular Outcomes in Patients With Chronic Kidney Disease. J Am Coll Cardiol. 2018 05 29; 71(21):2405-2414.
    View in: PubMed
    Score: 0.202
  26. Anti-Inflammatory Therapy With Canakinumab for the Prevention and Management of Diabetes. J Am Coll Cardiol. 2018 05 29; 71(21):2392-2401.
    View in: PubMed
    Score: 0.199
  27. Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial. Lancet. 2018 01 27; 391(10118):319-328.
    View in: PubMed
    Score: 0.195
  28. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. N Engl J Med. 2017 09 21; 377(12):1119-1131.
    View in: PubMed
    Score: 0.192
  29. Effect of interleukin-1ß inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial. Lancet. 2017 Oct 21; 390(10105):1833-1842.
    View in: PubMed
    Score: 0.192
  30. Primary Prevention With Statin Therapy in the Elderly: New Meta-Analyses From the Contemporary JUPITER and HOPE-3 Randomized Trials. Circulation. 2017 05 16; 135(20):1979-1981.
    View in: PubMed
    Score: 0.187
  31. Lipid-Reduction Variability and Antidrug-Antibody Formation with Bococizumab. N Engl J Med. 2017 04 20; 376(16):1517-1526.
    View in: PubMed
    Score: 0.186
  32. Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients. N Engl J Med. 2017 04 20; 376(16):1527-1539.
    View in: PubMed
    Score: 0.186
  33. Evaluating bococizumab, a monoclonal antibody to PCSK9, on lipid levels and clinical events in broad patient groups with and without prior cardiovascular events: Rationale and design of the Studies of PCSK9 Inhibition and the Reduction of vascular Events (SPIRE) Lipid Lowering and SPIRE Cardiovascular Outcomes Trials. Am Heart J. 2016 Aug; 178:135-44.
    View in: PubMed
    Score: 0.176
  34. Statin therapy and risk of fracture: results from the JUPITER randomized clinical trial. JAMA Intern Med. 2015 Feb; 175(2):171-7.
    View in: PubMed
    Score: 0.161
  35. Safety profile of subjects treated to very low low-density lipoprotein cholesterol levels (<30 mg/dl) with rosuvastatin 20 mg daily (from JUPITER). Am J Cardiol. 2014 Dec 01; 114(11):1682-9.
    View in: PubMed
    Score: 0.157
  36. Response to letter regarding article, "High-density lipoprotein cholesterol, size, particle number, and residual vascular risk after potent statin therapy". Circulation. 2014 Apr 29; 129(17):e481.
    View in: PubMed
    Score: 0.153
  37. High-density lipoprotein cholesterol, size, particle number, and residual vascular risk after potent statin therapy. Circulation. 2013 Sep 10; 128(11):1189-97.
    View in: PubMed
    Score: 0.146
  38. Rationale and design of the Cardiovascular Inflammation Reduction Trial: a test of the inflammatory hypothesis of atherothrombosis. Am Heart J. 2013 Aug; 166(2):199-207.e15.
    View in: PubMed
    Score: 0.142
  39. Lipoprotein(a), polymorphisms in the LPA gene, and incident venous thromboembolism among 21483 women. J Thromb Haemost. 2013 Jan; 11(1):205-8.
    View in: PubMed
    Score: 0.139
  40. On-treatment non-high-density lipoprotein cholesterol, apolipoprotein B, triglycerides, and lipid ratios in relation to residual vascular risk after treatment with potent statin therapy: JUPITER (justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin). J Am Coll Cardiol. 2012 Apr 24; 59(17):1521-8.
    View in: PubMed
    Score: 0.133
  41. The effect of rosuvastatin on incident pneumonia: results from the JUPITER trial. CMAJ. 2012 Apr 17; 184(7):E367-72.
    View in: PubMed
    Score: 0.132
  42. Comparison of associations of adherence to a Dietary Approaches to Stop Hypertension (DASH)-style diet with risks of cardiovascular disease and venous thromboembolism. J Thromb Haemost. 2012 Feb; 10(2):189-98.
    View in: PubMed
    Score: 0.131
  43. High-sensitivity C-reactive protein, statin therapy, and risks of atrial fibrillation: an exploratory analysis of the JUPITER trial. Eur Heart J. 2012 Feb; 33(4):531-7.
    View in: PubMed
    Score: 0.130
  44. Race, ethnicity, and the efficacy of rosuvastatin in primary prevention: the Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) trial. Am Heart J. 2011 Jul; 162(1):106-14.e2.
    View in: PubMed
    Score: 0.125
  45. Kinesin-like protein 6 (KIF6) polymorphism and the efficacy of rosuvastatin in primary prevention. Circ Cardiovasc Genet. 2011 Jun; 4(3):312-7.
    View in: PubMed
    Score: 0.124
  46. Effect of rosuvastatin on hemoglobin levels in patients with anemia and low-grade inflammation: a post hoc analysis of the JUPITER trial. J Clin Pharmacol. 2011 Oct; 51(10):1483-7.
    View in: PubMed
    Score: 0.121
  47. HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: an analysis from the JUPITER trial. Lancet. 2010 Jul 31; 376(9738):333-9.
    View in: PubMed
    Score: 0.117
  48. Statins for the primary prevention of cardiovascular events in women with elevated high-sensitivity C-reactive protein or dyslipidemia: results from the Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) and meta-analysis of women from primary prevention trials. Circulation. 2010 Mar 09; 121(9):1069-77.
    View in: PubMed
    Score: 0.114
  49. Rosuvastatin in the prevention of stroke among men and women with elevated levels of C-reactive protein: justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER). Circulation. 2010 Jan 05; 121(1):143-50.
    View in: PubMed
    Score: 0.113
  50. Number needed to treat with rosuvastatin to prevent first cardiovascular events and death among men and women with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin (JUPITER). Circ Cardiovasc Qual Outcomes. 2009 Nov; 2(6):616-23.
    View in: PubMed
    Score: 0.111
  51. Genetic risk factors in recurrent venous thromboembolism: A multilocus, population-based, prospective approach. Clin Chim Acta. 2009 Apr; 402(1-2):189-92.
    View in: PubMed
    Score: 0.107
  52. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet. 2009 Apr 04; 373(9670):1175-82.
    View in: PubMed
    Score: 0.107
  53. Lipid biomarkers, hormone therapy and the risk of venous thromboembolism in women. J Thromb Haemost. 2009 Apr; 7(4):588-96.
    View in: PubMed
    Score: 0.106
  54. An evaluation of candidate genes of inflammation and thrombosis in relation to the risk of venous thromboembolism: The Women's Genome Health Study. Circ Cardiovasc Genet. 2009 Feb; 2(1):57-62.
    View in: PubMed
    Score: 0.106
  55. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008 Nov 20; 359(21):2195-207.
    View in: PubMed
    Score: 0.104
  56. Effect of valsartan compared with valsartan/hydrochlorothiazide on plasma levels of cellular adhesion molecules: the Val-MARC trial. Heart. 2008 Mar; 94(3):e13.
    View in: PubMed
    Score: 0.100
  57. Baseline characteristics of participants in the JUPITER trial, a randomized placebo-controlled primary prevention trial of statin therapy among individuals with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein. Am J Cardiol. 2007 Dec 01; 100(11):1659-64.
    View in: PubMed
    Score: 0.097
  58. Effect of low-dose aspirin on the occurrence of venous thromboembolism: a randomized trial. Ann Intern Med. 2007 Oct 16; 147(8):525-33.
    View in: PubMed
    Score: 0.097
  59. Blood pressure and risk of developing type 2 diabetes mellitus: the Women's Health Study. Eur Heart J. 2007 Dec; 28(23):2937-43.
    View in: PubMed
    Score: 0.097
  60. Effects of random allocation to vitamin E supplementation on the occurrence of venous thromboembolism: report from the Women's Health Study. Circulation. 2007 Sep 25; 116(13):1497-503.
    View in: PubMed
    Score: 0.096
  61. Risk of cardiovascular events among women with high normal blood pressure or blood pressure progression: prospective cohort study. BMJ. 2007 Sep 01; 335(7617):432.
    View in: PubMed
    Score: 0.096
  62. Differential effect of soluble intercellular adhesion molecule-1 on the progression of atherosclerosis as compared to arterial thrombosis: a prospective analysis of the Women's Health Study. Atherosclerosis. 2008 Mar; 197(1):297-302.
    View in: PubMed
    Score: 0.095
  63. Awareness, accuracy, and predictive validity of self-reported cholesterol in women. J Gen Intern Med. 2007 May; 22(5):606-13.
    View in: PubMed
    Score: 0.093
  64. Relation between soluble intercellular adhesion molecule-1, homocysteine, and fibrinogen levels and race/ethnicity in women without cardiovascular disease. Am J Cardiol. 2007 May 01; 99(9):1246-51.
    View in: PubMed
    Score: 0.093
  65. High-sensitivity C-reactive protein, other markers of inflammation, and the incidence of macular degeneration in women. Arch Ophthalmol. 2007 Mar; 125(3):300-5.
    View in: PubMed
    Score: 0.093
  66. Impact of traditional and novel risk factors on the relationship between socioeconomic status and incident cardiovascular events. Circulation. 2006 Dec 12; 114(24):2619-26.
    View in: PubMed
    Score: 0.091
  67. Hormonal factors and risk of recurrent venous thrombosis: the prevention of recurrent venous thromboembolism trial. J Thromb Haemost. 2006 Oct; 4(10):2199-203.
    View in: PubMed
    Score: 0.089
  68. Valsartan, blood pressure reduction, and C-reactive protein: primary report of the Val-MARC trial. Hypertension. 2006 Jul; 48(1):73-9.
    View in: PubMed
    Score: 0.088
  69. The effect of statin therapy on lipoprotein associated phospholipase A2 levels. Atherosclerosis. 2005 Sep; 182(1):193-8.
    View in: PubMed
    Score: 0.084
  70. Perspective on selected issues in cardiovascular disease research with a focus on black Americans. Circulation. 2004 Jul 13; 110(2):e7-12.
    View in: PubMed
    Score: 0.077
  71. C-reactive protein levels among women of various ethnic groups living in the United States (from the Women's Health Study). Am J Cardiol. 2004 May 15; 93(10):1238-42.
    View in: PubMed
    Score: 0.077
  72. Hemoglobin A1c level and future cardiovascular events among women. Arch Intern Med. 2004 Apr 12; 164(7):757-61.
    View in: PubMed
    Score: 0.076
  73. Blood pressure and risk of secondary cardiovascular events in women: the Women's Antioxidant Cardiovascular Study (WACS). Circulation. 2004 Apr 06; 109(13):1623-9.
    View in: PubMed
    Score: 0.076
  74. Effect of physical activity on serum C-reactive protein. Am J Cardiol. 2004 Jan 15; 93(2):221-5.
    View in: PubMed
    Score: 0.075
  75. Plasma concentration of C-reactive protein and the calculated Framingham Coronary Heart Disease Risk Score. Circulation. 2003 Jul 15; 108(2):161-5.
    View in: PubMed
    Score: 0.072
  76. Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism. N Engl J Med. 2003 Apr 10; 348(15):1425-34.
    View in: PubMed
    Score: 0.070
  77. Alcohol consumption and plasma concentration of C-reactive protein. Circulation. 2003 Jan 28; 107(3):443-7.
    View in: PubMed
    Score: 0.070
  78. Testing the Effects of Disease-Modifying Antirheumatic Drugs on Vascular Inflammation in Rheumatoid Arthritis: Rationale and Design of the TARGET Trial. ACR Open Rheumatol. 2021 May 01.
    View in: PubMed
    Score: 0.062
  79. Association of Lipid, Inflammatory, and Metabolic Biomarkers With Age at Onset for Incident Coronary Heart Disease in Women. JAMA Cardiol. 2021 Apr 01; 6(4):437-447.
    View in: PubMed
    Score: 0.062
  80. Rosuvastatin for the prevention of venous thromboembolism: a pooled analysis of the HOPE-3 and JUPITER randomized controlled trials. Cardiovasc Res. 2021 Mar 10.
    View in: PubMed
    Score: 0.061
  81. Adverse Effects of Low-Dose Methotrexate in a Randomized Double-Blind Placebo-Controlled Trial: Adjudicated Hematologic and Skin Cancer Outcomes in the Cardiovascular Inflammation Reduction Trial. ACR Open Rheumatol. 2020 Dec; 2(12):697-704.
    View in: PubMed
    Score: 0.060
  82. Pulmonary Adverse Events in Patients Receiving Low-Dose Methotrexate in the Randomized, Double-Blind, Placebo-Controlled Cardiovascular Inflammation Reduction Trial. Arthritis Rheumatol. 2020 12; 72(12):2065-2071.
    View in: PubMed
    Score: 0.060
  83. Anti-Inflammatory HDL Function, Incident Cardiovascular Events, and Mortality: A Secondary Analysis of the JUPITER Randomized Clinical Trial. J Am Heart Assoc. 2020 09; 9(17):e016507.
    View in: PubMed
    Score: 0.059
  84. Group IIA Secretory Phospholipase A2, Vascular Inflammation, and Incident Cardiovascular Disease. Arterioscler Thromb Vasc Biol. 2019 06; 39(6):1182-1190.
    View in: PubMed
    Score: 0.054
  85. C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction. Circulation. 1998 May 26; 97(20):2007-11.
    View in: PubMed
    Score: 0.051
  86. Residual Risk of Atherosclerotic Cardiovascular Events in Relation to Reductions in Very-Low-Density Lipoproteins. J Am Heart Assoc. 2017 Dec 09; 6(12).
    View in: PubMed
    Score: 0.049
  87. Atherogenic Lipoprotein Determinants of Cardiovascular Disease and Residual Risk Among Individuals With Low Low-Density Lipoprotein Cholesterol. J Am Heart Assoc. 2017 Jul 21; 6(7).
    View in: PubMed
    Score: 0.048
  88. Cholesterol Efflux Capacity, High-Density Lipoprotein Particle Number, and Incident Cardiovascular Events: An Analysis From the JUPITER Trial (Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin). Circulation. 2017 Jun 20; 135(25):2494-2504.
    View in: PubMed
    Score: 0.047
  89. Age-specific incidence rates of venous thromboembolism among heterozygous carriers of factor V Leiden mutation. Ann Intern Med. 1997 Apr 01; 126(7):528-31.
    View in: PubMed
    Score: 0.047
  90. Discordance between Circulating Atherogenic Cholesterol Mass and Lipoprotein Particle Concentration in Relation to Future Coronary Events in Women. Clin Chem. 2017 04; 63(4):870-879.
    View in: PubMed
    Score: 0.046
  91. Association of N-Linked Glycoprotein Acetyls and Colorectal Cancer Incidence and Mortality. PLoS One. 2016; 11(11):e0165615.
    View in: PubMed
    Score: 0.046
  92. Circulating N-Linked Glycoprotein Side-Chain Biomarker, Rosuvastatin Therapy, and Incident Cardiovascular Disease: An Analysis From the JUPITER Trial. J Am Heart Assoc. 2016 07 13; 5(7).
    View in: PubMed
    Score: 0.044
  93. Association Between Markers of Inflammation and Total Stroke by Hypertensive Status Among Women. Am J Hypertens. 2016 09; 29(9):1117-24.
    View in: PubMed
    Score: 0.044
  94. Association of Lipoproteins, Insulin Resistance, and Rosuvastatin With Incident Type 2 Diabetes Mellitus : Secondary Analysis of a Randomized Clinical Trial. JAMA Cardiol. 2016 05 01; 1(2):136-45.
    View in: PubMed
    Score: 0.044
  95. Circulating N-Linked Glycoprotein Acetyls and Longitudinal Mortality Risk. Circ Res. 2016 Apr 01; 118(7):1106-15.
    View in: PubMed
    Score: 0.043
  96. Atherogenic Lipoprotein Subfractions Determined by Ion Mobility and First Cardiovascular Events After Random Allocation to High-Intensity Statin or Placebo: The Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) Trial. Circulation. 2015 Dec 08; 132(23):2220-9.
    View in: PubMed
    Score: 0.042
  97. Association Between High-Sensitivity C-Reactive Protein and Total Stroke by Hypertensive Status Among Men. J Am Heart Assoc. 2015 Sep 21; 4(9):e002073.
    View in: PubMed
    Score: 0.042
  98. High-sensitivity cardiac troponin I and B-type natriuretic Peptide as predictors of vascular events in primary prevention: impact of statin therapy. Circulation. 2015 May 26; 131(21):1851-60.
    View in: PubMed
    Score: 0.041
  99. Association of moderate alcohol consumption and plasma concentration of endogenous tissue-type plasminogen activator. JAMA. 1994 Sep 28; 272(12):929-33.
    View in: PubMed
    Score: 0.039
  100. Predisposing factors associated with development of persistent compared with paroxysmal atrial fibrillation. J Am Heart Assoc. 2014 May 01; 3(3):e000916.
    View in: PubMed
    Score: 0.038
  101. C-reactive protein and the incidence of macular degeneration: pooled analysis of 5 cohorts. JAMA Ophthalmol. 2013 Apr; 131(4):507-13.
    View in: PubMed
    Score: 0.035
  102. Pharmacogenetic warfarin dose refinements remain significantly influenced by genetic factors after one week of therapy. Thromb Haemost. 2012 Feb; 107(2):232-40.
    View in: PubMed
    Score: 0.032
  103. Socioeconomic status and incident type 2 diabetes mellitus: data from the Women's Health Study. PLoS One. 2011; 6(12):e27670.
    View in: PubMed
    Score: 0.032
  104. The relative importance of systolic versus diastolic blood pressure control and incident symptomatic peripheral artery disease in women. Vasc Med. 2011 Aug; 16(4):239-46.
    View in: PubMed
    Score: 0.031
  105. Perceptions of race/ethnic discrimination in relation to mortality among Black women: results from the Black Women's Health Study. Arch Intern Med. 2010 May 24; 170(10):896-904.
    View in: PubMed
    Score: 0.029
  106. Ability of VKORC1 and CYP2C9 to predict therapeutic warfarin dose during the initial weeks of therapy. J Thromb Haemost. 2010 Jan; 8(1):95-100.
    View in: PubMed
    Score: 0.028
  107. Socioeconomic status, blood pressure progression, and incident hypertension in a prospective cohort of female health professionals. Eur Heart J. 2009 Jun; 30(11):1378-84.
    View in: PubMed
    Score: 0.027
  108. Inflammation and progressive nephropathy in type 1 diabetes in the diabetes control and complications trial. Diabetes Care. 2008 Dec; 31(12):2338-43.
    View in: PubMed
    Score: 0.026
  109. Association of renin-angiotensin and endothelial nitric oxide synthase gene polymorphisms with blood pressure progression and incident hypertension: prospective cohort study. J Hypertens. 2008 Sep; 26(9):1780-6.
    View in: PubMed
    Score: 0.026
  110. Combination therapy versus monotherapy as initial treatment for stage 2 hypertension: a prespecified subgroup analysis of a community-based, randomized, open-label trial. Clin Ther. 2008 Apr; 30(4):661-72.
    View in: PubMed
    Score: 0.025
  111. Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin Pharmacol Ther. 2008 Sep; 84(3):326-31.
    View in: PubMed
    Score: 0.025
  112. Renin-angiotensin and endothelial nitric oxide synthase gene polymorphisms are not associated with the risk of incident type 2 diabetes mellitus: a prospective cohort study. J Intern Med. 2008 Apr; 263(4):376-85.
    View in: PubMed
    Score: 0.024
  113. Natriuretic peptide precursor a gene polymorphisms and risk of blood pressure progression and incident hypertension. Hypertension. 2007 Dec; 50(6):1114-9.
    View in: PubMed
    Score: 0.024
  114. D-dimer, factor VIII coagulant activity, low-intensity warfarin and the risk of recurrent venous thromboembolism. J Thromb Haemost. 2006 Jun; 4(6):1208-14.
    View in: PubMed
    Score: 0.022
  115. Effect of intensive glycemic control on levels of markers of inflammation in type 1 diabetes mellitus in the diabetes control and complications trial. Circulation. 2005 May 17; 111(19):2446-53.
    View in: PubMed
    Score: 0.020
  116. High levels of plasma C-reactive protein and future risk of age-related cataract. Ann Epidemiol. 1999 Apr; 9(3):166-71.
    View in: PubMed
    Score: 0.013
  117. Early versus delayed angiotensin-converting enzyme inhibition therapy in acute myocardial infarction. The healing and early afterload reducing therapy trial. Circulation. 1997 Jun 17; 95(12):2643-51.
    View in: PubMed
    Score: 0.012
  118. Hypertension and borderline isolated systolic hypertension increase risks of cardiovascular disease and mortality in male physicians. Circulation. 1997 Mar 04; 95(5):1132-7.
    View in: PubMed
    Score: 0.012
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.